All In MedTech

Device Trial Radar · NCT06263946

Essilor® Stellest® Lenses Multicentre European Study (SLOMES)

Post Market Clinical Follow-up Study to Demonstrate the Efficacy, Safety, Acceptability and Quality of Life Implications of Essilor® Stellest® Spectacle Lenses in Slowing Myopia Progression in Children and Adolescents.

Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Mar 22, 2024

Primary completion

May 4, 2027

Study completion May 4, 2027

Sponsor

Lead sponsor
Essilor InternationalNot on our public-company list
Sponsor type
Industry
First posted
Feb 16, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 6 years, up to 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this post-market clinical follow up Study is to demonstrate the efficacy, safety, acceptability, and quality of life implications of Essilor® Stellest® spectacle lenses in slowing myopia progression in European children and adolescents. Participants will receive Essilor® Stellest® at inclusion visit and will be asked for a full time wear (\>12 hours daily) for 24 months. The primary endpoints are the change in axial length and cycloplegic autorefraction from baseline to 24 months compared to expected change based on axial length and refraction centile positions at baseline.

Conditions

  • Myopia

Interventions

  • Essilor® Stellest® spectacle lensesDevice

    patients will be asked to wear Essilor® Stellest® spectacle lenses more than 12 hours per day for 24 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in cycloplegic axial lengthTime frame: from baseline to 24 months
  2. Change in cycloplegic autorefractionTime frame: from baseline to 24 months

Locations

3 sites in 3 countries. Site status is shown where the registry gives one.

  • Hôpital Fondation Adolphe de Rothschild - Ophthalmology Department

    Paris, France

  • Centre for Eye Research Ireland (CERI) - TU DUBLIN

    Dublin, Ireland

  • Erasmus Medical Center

    Rotterdam, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.